West Jordan man allegedly kills roommate's dog, claiming it was a robot
WEST JORDAN, Utah () — A West Jordan man is in custody after he allegedly killed his roommate's dog, claiming it was a robot that had been 'mimicking him,' according to court documents.
Drake Montgomery, 23, was booked into the Salt Lake County jail on third-degree felony charges of torturing a companion animal and obstruction of justice, as well as second-degree felony arson.
Police say Montgomery was taken into custody on Monday, June 2, shortly after he allegedly attempted to start a fire in Emigration Canyon. After an investigation, officers reported Montgomery had allegedly stabbed his roommate's dog and was in the canyon attempting to dispose of the evidence.
Associate Chief Justice John Pearce to step down from Utah Supreme Court
The dog was later found in the trunk of Montgomery's vehicle, along with burnt rags, cleaning fluid and a shovel, according to court records.
While interviewing with detectives, Montgomery allegedly admitted to punching the dog multiple times and trying to choke the dog. When the dog began to fight back, he reportedly admitted to stabbing it several times.
According to court documents, Montgomery believed the dog had been mimicking him and was 'causing him significant stress.'
'He expressed a belief that the dog was not real, but rather a robot, as the dog was neuralinked to him, and he could no longer handle the situation,' the arresting officer wrote in the affidavit.
Montgomery was booked on the aforementioned charges and has been ordered to be held without bail, pending a pretrial hearing.
Charges are allegations only. All arrested persons are presumed innocent unless and until proven guilty beyond a reasonable doubt.
Republicans want to stop judges from issuing nationwide injunctions
Self-regulating as a parent
Schumer warns of rise in antisemitism
White House sends Congress request for $9.4 billion in DOGE cuts
Braylynn's battle with Nonketotic Hyperglycinemia (NKH)
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
US health care is rife with high costs and deep inequities, and that's no accident – a public health historian explains how the system was shaped to serve profit and politicians
A few years ago, a student in my history of public health course asked why her mother couldn't afford insulin without insurance, despite having a full-time job. I told her what I've come to believe: The U.S. health care system was deliberately built this way. People often hear that health care in America is dysfunctional – too expensive, too complex and too inequitable. But dysfunction implies failure. What if the real problem is that the system is functioning exactly as it was designed to? Understanding this legacy is key to explaining not only why reform has failed repeatedly, but why change remains so difficult. I am a historian of public health with experience researching oral health access and health care disparities in the Deep South. My work focuses on how historical policy choices continue to shape the systems we rely on today. By tracing the roots of today's system and all its problems, it's easier to understand why American health care looks the way it does and what it will take to reform it into a system that provides high-quality, affordable care for all. Only by confronting how profit, politics and prejudice have shaped the current system can Americans imagine and demand something different. My research and that of many others show that today's high costs, deep inequities and fragmented care are predictable features developed from decades of policy choices that prioritized profit over people, entrenched racial and regional hierarchies, and treated health care as a commodity rather than a public good. Over the past century, U.S. health care developed not from a shared vision of universal care, but from compromises that prioritized private markets, protected racial hierarchies and elevated individual responsibility over collective well-being. Employer-based insurance emerged in the 1940s, not from a commitment to worker health but from a tax policy workaround during wartime wage freezes. The federal government allowed employers to offer health benefits tax-free, incentivizing coverage while sidestepping nationalized care. This decision bound health access to employment status, a structure that is still dominant today. In contrast, many other countries with employer-provided insurance pair it with robust public options, ensuring that access is not tied solely to a job. In 1965, Medicare and Medicaid programs greatly expanded public health infrastructure. Unfortunately, they also reinforced and deepened existing inequalities. Medicare, a federally administered program for people over 64, primarily benefited wealthier Americans who had access to stable, formal employment and employer-based insurance during their working years. Medicaid, designed by Congress as a joint federal-state program, is aimed at the poor, including many people with disabilities. The combination of federal and state oversight resulted in 50 different programs with widely variable eligibility, coverage and quality. Southern lawmakers, in particular, fought for this decentralization. Fearing federal oversight of public health spending and civil rights enforcement, they sought to maintain control over who received benefits. Historians have shown that these efforts were primarily designed to restrict access to health care benefits along racial lines during the Jim Crow period of time. Today, that legacy is painfully visible. States that chose not to expand Medicaid under the Affordable Care Act are overwhelmingly located in the South and include several with large Black populations. Nearly 1 in 4 uninsured Black adults are uninsured because they fall into the coverage gap – unable to access affordable health insurance – they earn too much to qualify for Medicaid but not enough to receive subsidies through the Affordable Care Act's marketplace. The system's architecture also discourages care aimed at prevention. Because Medicaid's scope is limited and inconsistent, preventive care screenings, dental cleanings and chronic disease management often fall through the cracks. That leads to costlier, later-stage care that further burdens hospitals and patients alike. Meanwhile, cultural attitudes around concepts like 'rugged individualism' and 'freedom of choice' have long been deployed to resist public solutions. In the postwar decades, while European nations built national health care systems, the U.S. reinforced a market-driven approach. Publicly funded systems were increasingly portrayed by American politicians and industry leaders as threats to individual freedom – often dismissed as 'socialized medicine' or signs of creeping socialism. In 1961, for example, Ronald Reagan recorded a 10-minute LP titled 'Ronald Reagan Speaks Out Against Socialized Medicine,' which was distributed by the American Medical Association as part of a national effort to block Medicare. The health care system's administrative complexity ballooned beginning in the 1960s, driven by the rise of state-run Medicaid programs, private insurers and increasingly fragmented billing systems. Patients were expected to navigate opaque billing codes, networks and formularies, all while trying to treat, manage and prevent illness. In my view, and that of other scholars, this isn't accidental but rather a form of profitable confusion built into the system to benefit insurers and intermediaries. Even well-meaning reforms have been built atop this structure. The Affordable Care Act, passed in 2010, expanded access to health insurance but preserved many of the system's underlying inequities. And by subsidizing private insurers rather than creating a public option, the law reinforced the central role of private companies in the health care system. The public option – a government-run insurance plan intended to compete with private insurers and expand coverage – was ultimately stripped from the Affordable Care Act during negotiations due to political opposition from both Republicans and moderate Democrats. When the U.S. Supreme Court made it optional in 2012 for states to offer expanded Medicaid coverage to low-income adults earning up to 138% of the federal poverty level, it amplified the very inequalities that the ACA sought to reduce. These decisions have consequences. In states like Alabama, an estimated 220,000 adults remain uninsured due to the Medicaid coverage gap – the most recent year for which reliable data is available – highlighting the ongoing impact of the state's refusal to expand Medicaid. In addition, rural hospitals have closed, patients forgo care, and entire counties lack practicing OB/GYNs or dentists. And when people do get care – especially in states where many remain uninsured – they can amass medical debt that can upend their lives. All of this is compounded by chronic disinvestment in public health. Federal funding for emergency preparedness has declined for years, and local health departments are underfunded and understaffed. The COVID-19 pandemic revealed just how brittle the infrastructure is – especially in low-income and rural communities, where overwhelmed clinics, delayed testing, limited hospital capacity, and higher mortality rates exposed the deadly consequences of neglect. Change is hard not because reformers haven't tried before, but because the system serves the very interests it was designed to serve. Insurers profit from obscurity – networks that shift, formularies that confuse, billing codes that few can decipher. Providers profit from a fee-for-service model that rewards quantity over quality, procedure over prevention. Politicians reap campaign contributions and avoid blame through delegation, diffusion and plausible deniability. This is not an accidental web of dysfunction. It is a system that transforms complexity into capital, bureaucracy into barriers. Patients – especially the uninsured and underinsured – are left to make impossible choices: delay treatment or take on debt, ration medication or skip checkups, trust the health care system or go without. Meanwhile, I believe the rhetoric of choice and freedom disguises how constrained most people's options really are. Other countries show us that alternatives are possible. Systems in Germany, France and Canada vary widely in structure, but all prioritize universal access and transparency. Understanding what the U.S. health care system is designed to do – rather than assuming it is failing unintentionally – is a necessary first step toward considering meaningful change. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Zachary W. Schulz, Auburn University Read more: Buyouts can bring relief from medical debt, but they're far from a cure Public health and private equity: What the Walgreens buyout could mean for the future of pharmacy care Migrants often can't access US health care until they are critically ill – here are some of the barriers they face Zachary W. Schulz does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Yahoo
2 hours ago
- Yahoo
Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025
Key presentations include two updates from a phase 3 trial evaluating investigational treatment with Mim8 (denecimig) and five assessing treatment outcomes with concizumab in hemophilia A phase 3 trial analysis from FRONTIER5 will evaluate the safety of switching directly from emicizumab to Mim8 (denecimig) in people living with hemophilia A/B Findings from explorer7 and explorer8 phase 3 trials will assess data including non-joint bleeds, annualized bleeding rates and additional studies including thrombin generation with concizumab in hemophilia A/B PLAINSBORO, N.J., June 6, 2025 /PRNewswire/ -- Novo Nordisk today announced that new hemophilia data will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, June 21-25. Key data presentations across both hemophilia A and B (HA and HB), with and without inhibitors, will share insights on clotting, thrombin generation, bleeding episodes and medication impact, patient administration preferences, physician treatment satisfaction, and global real-world diagnosis and treatment data for joint bleeds. "At Novo Nordisk, we believe understanding the whole person and their journey is essential to addressing the unmet needs in people with hemophilia. Our research is rooted in a deep understanding of the hemophilia community, aiming to drive critical advancements across rare blood disorders in order to help address these unmet needs," said Stephanie Seremetis, Chief Medical Officer and CVP for Rare Disease at Novo Nordisk. "Through this latest research, we are honored to build on our long-standing legacy in rare blood disorders to support patients who face the challenges of this complex condition." New phase 3 data will be presented on Mim8, an investigational mimetic therapy designed to replicate the function of missing clotting factors.1 Analysis from the phase 3 FRONTIER5 trial will assess the safety and preferences of people with HA, with and without inhibitors, who switch from emicizumab to Mim8. In addition, new data from two prospective, multicenter, open label, phase 3 trials (explorer7 and explorer8) will investigate joint bleeds, non-joint bleeds, and annualized bleeding rate with preventive concizumab being investigated versus on-demand treatment across both HA and HB, with and without inhibitors. Summary of presentationsAccepted data at the 33rd ISTH Congress includes the following poster and oral presentations. Additional information can be found on the ISTH website. Full details of Novo Nordisk abstracts to be presented: Abstract title Abstract presentationdetails Hemophilia Investigational Mim8 FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab Oral presentation June 22 2:45-4:00 pm EST OC 20.4 Evaluating pen-injector handling and PROs in patients switching from emicizumab to Mim8 in FRONTIER5 Poster presentation June 23 1:45-2:45 pm EST PB0812 Mim8 enhances procoagulant activity of select hemophilia B-causing Factor IX variants (research collaboration) Oral presentation June 21 1:00-1:15 pm EST OC 03.1 Concizumab Non-joint bleeds in patients with hemophilia A or B with inhibitors: Concizumab explorer7 study Poster presentation June 23 1:45-2:45 pm EST PB0851 Annualized bleeding rates in hemophilia A/B and target joints: Concizumab explorer8 study Oral presentation June 24 2:45-4:00 pm EST OC 59.2 The effect of concizumab on thrombin generation in FVII deficient plasma Poster presentation June 24 1:45-2:45 pm EST PB1478 ISS study: TFPI slows prothombinase assembly when concizumab is bound to its second Kunitz domain Poster presentation June 24 1:45-2:45 pm EST PB1358 Taiwan study: Real-world efficacy of concizumab prophylaxis in a patient with hemophilia B and inhibitors Poster presentation June 23 1:45-2:45 pm EST PB0869 Pre-clinical data & general hemophilia In vitro activity of Inno8 in global hemostatic assays alone and with other hemostatic agents Oral presentation June 23 2:45-4:00 pm EST OC 39.5 Genomic integration of FVIII transgene in hepatocytes restores durable FVIII activity in vivo Oral presentation June 24 9:30-10:45 am EST OC 51.2 US physician-reported prophylactic treatment satisfaction and joint health of people with hemophilia Poster presentation June 24 1:45-2:45 pm EST PB1485 Joint bleed diagnosis and treatment delays in people with hemophilia: Global real-world data Poster presentation June 24 1:45-2:45 pm EST PB1423 About hemophiliaHemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.2 It is estimated to affect approximately 1,125,000 people worldwide.3 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing. Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX (FIX).2 Hemophilia is often treated by replacing the missing clotting factor via intravenous infusions, also known as replacement therapy. However, sometimes the body can produce inhibitors as an immune response to the clotting factor replacement therapy. When this happens, the therapy may not work and can limit treatment options.5 About Novo NordiskNovo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a U.S. presence spanning 40 years, Novo Nordisk U.S. is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US)+1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global)+45 3079 6656 azey@ Ida Schaap Melvold (Global)+45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References Østergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138(14):1258-1268. MedlinePlus. Hemophilia. Accessed May 2025. Available at Iorio A, Stonebraker JS, Chambost H, et al.; Data and demographics committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546. Centers for Disease Control and Prevention (CDC). Treatment of hemophilia. Accessed May 2025. Available at Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25NNG00026 June 2025 View original content to download multimedia: SOURCE Novo Nordisk Sign in to access your portfolio
Politico
2 hours ago
- Politico
WHO sounds the alarm as US measles cases mount
Presented by Driving The Day WHO SPEAKS UP ON MEASLES — President Donald Trump might not care for the World Health Organization's advice, but that isn't stopping one of its top officials from warning his administration about what's at stake as measles cases accumulate in the U.S. Dr. Katherine O'Brien, the WHO's vaccines director, told POLITICO's Carmen Paun that U.S. political leaders should clearly endorse and promote measles vaccination to prevent the country from losing its disease-elimination status — and become a location that gives rise to future outbreaks that can easily spread domestically and abroad among travelers. If the disease spreads continuously for a year, it would be considered endemic for the first time in 25 years. 'It's really a sign of a country going backwards in terms of their ability to protect people,' O'Brien said. Why it matters: O'Brien said 'leadership voices really matter' when people consider medical interventions for their children. If one family is influenced enough to decline the measles, mumps and rubella vaccine for their child, that's 'one child too many,' she said, given how highly contagious the virus is. Measles is 'not just a fever and a rash that people get over,' O'Brien said. So far this year, three unvaccinated people — including two young girls — have died from the disease in the U.S. Before the most recent outbreak, the last U.S. measles death occurred in 2015. Background: HHS Secretary Robert F. Kennedy Jr. has couched his promotion of the MMR shot with statements emphasizing that vaccination is a personal choice. Before he ran for president and then entered government, Kennedy founded Children's Health Defense, an anti-vaccine nonprofit that suggests shots cause a slew of pediatric medical problems such as autism, asthma and developmental delays. Kennedy has also inaccurately asserted that the MMR vaccine contains cells from aborted fetuses and has touted supplements like vitamin A as a disease treatment. HHS has defended the secretary's measles response, calling 'claims' that he's 'spreading misinformation or undermining vaccine confidence … flat-out false.' WELCOME TO FRIDAY PULSE. I'm FDA reporter Lauren Gardner, filling in for Kelly today. Pass along your tips, scoops and feedback to lgardner@ and khooper@ and follow along @Gardner_LM or @Kelhoops. POLITICO PRO SPACE — Need an insider's guide to the politics behind the new space race? From battles over sending astronauts to Mars to the ways space companies are vying to influence regulators, this weekly newsletter decodes the personalities, policy and power shaping the final frontier. Find out more. In Congress THIRD RAIL NO MORE? Senate Republicans are considering ways to incorporate Medicare cuts into their domestic spending package to help offset its cost — a move that could divide a party that can't afford many defections to pass the president's signature legislation, POLITICO's Jordain Carney, Meredith Lee Hill and Robert King report. The House version of President Donald Trump's big beautiful bill includes cuts to Medicaid, the government health insurance program for low-income people and those with disabilities. But cuts to Medicare — which insures those 65 and older — are widely seen as politically dangerous. The idea percolated in private meetings this week as GOP leaders try to placate budget hardliners who want more spending cuts in the package ahead of a self-imposed July 4 deadline for passage. And some Republicans believe Trump supports Medicare cuts — provided they're limited to targeting 'waste, fraud and abuse' — despite the potential for backlash from rank-and-file senators and House moderates who already sank efforts to touch the program. HEADING TO THE HUMPHREY BUILDING — The Senate confirmed Jim O'Neill on Thursday in a 52-43 vote to be HHS's deputy secretary, your morning host writes. O'Neill, a George W. Bush-era HHS official who's close with early Trump supporter and tech billionaire Peter Thiel, will be the department's No. 2 official charged with managing operations. AROUND THE AGENCIES FDA'S RARE DISEASE DRUG APPROACH — The FDA's leading biologics regulator said Thursday that he was open to using alternative measurement methods when evaluating rare-disease therapies, combining what he called 'gold-standard science and common sense' in the approval process. 'We will rapidly make available therapies at the first sign or promise of biomedical success or action, but we're also going to follow up overall survival and quality of life on the back end,' Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, said during an agency roundtable on cell and gene therapies. The remarks were notable given Prasad's history of criticizing past FDA approvals of certain treatments, including a controversial Duchenne muscular dystrophy gene therapy and certain cancer drugs, using surrogate markers. Prasad added he's often asked whether he's 'solely' interested in randomized controlled trials and said he's open to a variety of methodologies demonstrating a drug's benefit. Background: His remarks come weeks after he and Commissioner Marty Makary unveiled a new Covid-19 vaccine framework that limits approvals of future formulation changes to people 65 and older and younger individuals with an underlying condition — and requiring new RCTs to prove the shots are safe and effective for young, healthy people. Cell and gene therapies are often discussed in the context of rare diseases as the technologies can address root causes instead of solely managing symptoms. But a condition's rarity hinders a company's ability to conduct a large-scale trial for a drug candidate, an issue with which regulators and industry have long struggled. The FDA launched a rare disease 'hub' last year to better align its drug and biologics regulators in their approach to considering those therapies for the market. NIH LOOKS TO AI — The National Institutes of Health is building an AI strategy to help HHS Secretary Robert F. Kennedy Jr. target chronic disease, POLITICO's Ruth Reader reports. Principal Deputy Director Matthew Memoli announced the plan Thursday, asking the public to weigh in at the Coalition for Health AI's Innovation Summit at Stanford University. NIH wants industry to comment on both the broad approach and the specific actions the administration should take in developing the strategy. The agency plans to create a new website to highlight its AI work. 'Addressing this crisis is going to require large-scale efforts — research that's going to generate large amounts of data — and we are going to need all the tools available to us in order to try to address this,' Memoli said. Names in the News Courtney Rhodes is now head of news and media relations at the U.S. Travel Association. She was previously a spokesperson at the FDA. The Health Resources and Services Administration announced its new 34-member board of directors for the Organ Procurement and Transplantation Network. WHAT WE'RE READING House FDA appropriators advanced their fiscal 2026 spending measure Thursday for the agency and the U.S. Department of Agriculture, POLITICO's David Lim reports. Infectious disease and other medical experts fear HHS's changes to Covid-19 vaccine recommendations will make it more difficult to immunize people by complicating discussions with providers and likely leading to fewer places stocking them, Stat's Helen Branswell writes.
